Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,122.79
(
-0.22%
)
US TECH 100
26,355.00
(
0.20%
)
Dow Jones
48,829.62
(
-0.64%
)
Brent Oil
110.73
(
6.05%
)
Bitcoin
75,913.37
(
-0.57%
)
News Focus
News Focus
Post# of 517642
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

georgejjl

Send PM Follow Ignore
Followers 147
Posts 26209
Boards Moderated 0
Alias Born 04/08/2004

georgejjl

Re: Investor2014 post# 437884

Thursday, 11/02/2023 2:13:06 PM

Thursday, November 02, 2023 2:13:06 PM

Post# of 517642
Investor2014: You are WRONG!!!

The following is from the results of the Phase 2a trial with Blarcamesine for the treatment of Alzheimer’s disease.

75% of APOE e4 carriers in the high Anavex 2-73 concentration cohort

Notice the significant covariates identified in he MMRM-LME model are:

SIGMAR1 (p<0.0080)

COMT (p<0.0014) and

APOE e4 (p<0.0001)

See slide #15 and #16

http://www.arianapharma.com/wp-content/uploads/2019/03/ANAVEX2-73_CTAD_2018_Presentation_v2.pdf

GOD bless,
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News